{"id":"cyclophosphamide-bortezomib-dexamethasone-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclophosphamide is an alkylating agent that cross-links DNA and triggers cell death. Bortezomib inhibits the 26S proteasome, preventing degradation of pro-apoptotic proteins and causing accumulation of misfolded proteins in cancer cells. Dexamethasone is a corticosteroid that enhances the anti-tumor effect and reduces inflammation. Together, these agents target multiple pathways to overcome drug resistance in hematologic malignancies.","oneSentence":"This three-drug combination kills cancer cells through DNA damage (cyclophosphamide), proteasome inhibition (bortezomib), and glucocorticoid immunosuppression (dexamethasone).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:18.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (induction therapy)"},{"name":"Light chain deposition disease"},{"name":"Waldenström macroglobulinemia"}]},"trialDetails":[{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT04512235","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-11-03","conditions":"AL Amyloidosis","enrollment":281},{"nctId":"NCT04504825","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-08-25","conditions":"AL Amyloidosis","enrollment":125},{"nctId":"NCT04181827","phase":"PHASE3","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-12","conditions":"Multiple Myeloma","enrollment":419},{"nctId":"NCT06577025","phase":"PHASE2","title":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-08-20","conditions":"Multiple Myeloma","enrollment":43},{"nctId":"NCT07149857","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-10-03","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT04923893","phase":"PHASE3","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-19","conditions":"Multiple Myeloma","enrollment":743},{"nctId":"NCT06142396","phase":"EARLY_PHASE1","title":"Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","status":"RECRUITING","sponsor":"Augusta University","startDate":"2024-11-01","conditions":"Multiple Myeloma, Renal Failure","enrollment":30},{"nctId":"NCT06627309","phase":"","title":"Rapid dFLC Response Predict CHR in AL Amyloidosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-10-26","conditions":"Systemic AL Amyloidosis","enrollment":50},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT04656951","phase":"PHASE2","title":"Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cologne","startDate":"2021-06-01","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT02844322","phase":"PHASE4","title":"The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-05","conditions":"Waldenström Macroglobulinemia","enrollment":35},{"nctId":"NCT04973137","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis","status":"TERMINATED","sponsor":"Prothena Biosciences Ltd.","startDate":"2021-08-30","conditions":"Light Chain (AL) Amyloidosis","enrollment":208},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT00734877","phase":"PHASE3","title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":382},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":5000},{"nctId":"NCT04304144","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-03-18","conditions":"AL Amyloidosis","enrollment":25},{"nctId":"NCT06457464","phase":"","title":"Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-07-01","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT03188172","phase":"PHASE2","title":"MUK Nine b: OPTIMUM Treatment Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Leeds","startDate":"2017-09-28","conditions":"Multiple Myeloma","enrollment":95},{"nctId":"NCT02513186","phase":"PHASE1","title":"Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-09-30","conditions":"Plasma Cell Myeloma","enrollment":90},{"nctId":"NCT02188368","phase":"PHASE2","title":"Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-07-07","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT03759093","phase":"PHASE2, PHASE3","title":"CURATE.AI Optimized Modulation for Multiple Myeloma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2023-09-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT01849783","phase":"PHASE2","title":"Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Margarida Magalhaes-Silverman","startDate":"2013-04-04","conditions":"Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease","enrollment":41},{"nctId":"NCT05147493","phase":"PHASE2","title":"A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment","status":"UNKNOWN","sponsor":"Hellenic Society of Hematology","startDate":"2022-04","conditions":"Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell","enrollment":51},{"nctId":"NCT03670173","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Assessments of Osalmid in Multiple Myeloma","status":"UNKNOWN","sponsor":"Shanghai 10th People's Hospital","startDate":"2018-10-01","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT00570180","phase":"PHASE2","title":"Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2008-08-25","conditions":"Multiple Myeloma","enrollment":36},{"nctId":"NCT01383759","phase":"NA","title":"Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-06-24","conditions":"Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD)","enrollment":20},{"nctId":"NCT03390387","phase":"NA","title":"Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2015-11","conditions":"Childhood Acute Lymphoblastic Leukemia","enrollment":4000},{"nctId":"NCT04065308","phase":"PHASE2","title":"Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2019-01-14","conditions":"Multiple Myeloma in Relapse, Plasmacytoma, Daratumumab","enrollment":33},{"nctId":"NCT03982771","phase":"PHASE2","title":"BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-01-01","conditions":"Idiopathic Multicentric Castleman's Disease","enrollment":30},{"nctId":"NCT02518750","phase":"PHASE2","title":"Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-11-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell","enrollment":3},{"nctId":"NCT00413959","phase":"PHASE2","title":"VELCADE,Rituximab,Cyclophosphamide and Decadron","status":"TERMINATED","sponsor":"Oncology Specialists, S.C.","startDate":"2006-08","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, B-Cell","enrollment":12},{"nctId":"NCT01554852","phase":"PHASE3","title":"Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":4420},{"nctId":"NCT02559154","phase":"PHASE4","title":"Modified Bortezomib-based Combination Therapy for Multiple Myeloma","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT01208818","phase":"PHASE3","title":"Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-06","conditions":"Chronic Renal Failure With Uremic Nephropathy","enrollment":284},{"nctId":"NCT00670631","phase":"PHASE2","title":"Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment","status":"COMPLETED","sponsor":"Guido Tricot","startDate":"2008-02","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT02086942","phase":"PHASE2","title":"Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.","status":"UNKNOWN","sponsor":"Yongping Zhai","startDate":"2013-08","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT01548573","phase":"PHASE2","title":"Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2012-05","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT01729338","phase":"PHASE2","title":"Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma","status":"TERMINATED","sponsor":"Duke University","startDate":"2012-12-19","conditions":"Multiple Myeloma","enrollment":17},{"nctId":"NCT02362165","phase":"PHASE3","title":"CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-04","conditions":"Multiple Myeloma","enrollment":236},{"nctId":"NCT01537861","phase":"EARLY_PHASE1","title":"Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-06","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT00531453","phase":"PHASE2","title":"A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Multiple Myeloma","enrollment":98},{"nctId":"NCT01114048","phase":"PHASE2","title":"Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)","status":"UNKNOWN","sponsor":"Chonnam National University Hospital","startDate":"2010-03","conditions":"Multiple Myeloma","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cyclophosphamide + Bortezomib + Dexamethasone regimen","genericName":"Cyclophosphamide + Bortezomib + Dexamethasone regimen","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This three-drug combination kills cancer cells through DNA damage (cyclophosphamide), proteasome inhibition (bortezomib), and glucocorticoid immunosuppression (dexamethasone). Used for Multiple myeloma (induction therapy), Light chain deposition disease, Waldenström macroglobulinemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}